GlassScriptPhysician profile
Bradly C Newcom
NPI 1912004649
$3,831.52
in general payments reported to CMS, 2019-2025
27 companies · $753 in 2025
The $753 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $176 · 2021: $148 · 2022: $502 · 2023: $982 · 2024: $815 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,550.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $603.75 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $522.19 | 2022-2024 | Austedo Xr, Austedo |
| Corium, LLC | $387.13 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $357.56 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $347.10 | 2019-2025 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $223.39 | 2019-2021 | |
| Lundbeck LLC | $220.56 | 2020-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $199.54 | 2021-2024 | Trintellix |
| Alkermes, INC. | $165.94 | 2019-2025 | Lybalvi |
| Vanda Pharmaceuticals INC. | $129.16 | 2019-2024 | Fanapt, Hetlioz |
| Pfizer INC. | $118.47 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $69.83 | 2022-2023 | Jornay Pm |
| Biodelivery Sciences International, INC. | $69.74 | 2019-2021 | |
| Si-Bone, INC. | $66.75 | 2020-2023 | |
| Avanos Medical | $63.21 | 2024-2025 | Standard Rf Disposables, Coolief* Cooled Radiofrequency |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $54.71 | 2019-2023 | Senza |
| Idorsia Pharmaceuticals US INC | $42.64 | 2023 | Quviviq |
| Amgen INC. | $33.27 | 2019-2024 | Evenity, Prolia |
| Medtronic USA, INC. | $24.66 | 2019 | |
| Averitas Pharma INC. | $24.21 | 2024 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.97 | 2025 | Relistor |
| Sanofi-Aventis U.S. LLC | $19.27 | 2019 | |
| Medtronic, INC. | $18.12 | 2025 | Inceptiv |
| Supernus Pharmaceuticals, INC. | $13.96 | 2023 | Qelbree |
| Novartis Pharmaceuticals Corporation | $13.04 | 2020 | |
| Abbvie INC. | $12.64 | 2022 | |
| Daiichi Sankyo INC. | $10.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradly Newcom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.